Bioequivalence Study of Atorvastatin Tablets

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 9, 2004, Pages 573-577

  Koytchev, Rossen ^a   Ozalp, Yildiz ^b   Erenmemisoglu, Aydin ^c   Van Der Meer, Mike John ^d   Alpan, Recep Serdar ^b  

^a Cooperative Clinical Drug Research and Development ^*  (Germany)

^b EIS Eczacibasi Ilac Sanayi ve T   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

^d Trident Bioanalytics Ltd   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; KOLESTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SCREENING; DRUG TOLERANCE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRROLES; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 4644302204     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297051     Document Type: Article

References (14)

1. Blum, C., Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Am. J. Cardiol. 73 (Suppl. D), 3D (1994)
2. Rackley, C., Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin. Cardiol. 19, 683 (1996)
3. OʼnConnor, P., Freely, J., Shepard, J., Lipid lowering drugs. BMJ 300, 667 (1990)
4. Lea, A., McTavish, D., Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 53, 828 (1997)
5. Malhotra, H., Goa, K., Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61, 1835 (2001)
6. Michniewicz, B., Black, A., Sinz, M. et al., In vitro and in vivo metabolism of atorvastatin (CI-981). ISSX Proc. 6, 93 (1994) (abstract)
7. Radulovic, L., Cilla, D., Posvar, E., Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 35, 990 (1995)
8. Shah, V. P., Midha, K. K., Dighe, S. et al., Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81, 309 (1992)
9. Hauschke, D., Steinijans, V., Diletti, E., A distribution free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 72 (1990)
10. Product Information Lipitorürg, 1999
11. Stern, R., Yang, B.-B., Hounslow, H. et al. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 40, 616 (2000)
12. CPMP Note for Guidance: Investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98 (1998)
13. Cilla, D. D., Whitfield, L. R., Gibson, D. M. et al., Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharm. Ther. 60, 687 (1996)
14. Posvar, E. L., Radulovic, L. L., Cilla, D. D. et al., Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J. Clin. Pharmacol. 36, 728 (1996)